Abstract:OBJECTIVE:To observe the in vivo therapeutic effects of murine Flt3 ligand (mFL) mediated by recombinant adenoviral vector on murine liver cancer.METHODS:Murine liver cancer cell line Hepal-6 was infected with adenovirus in vitro. The infection efficacy was measured by green fluorescence protein (GFP) expression and the amount of mFL in supernatant was measured by ELISA 48 hrs following infection of Hepal-6. AdmFL, Ad-null, and PBS were added into the culture of Hepal-6 cells, the number of cells was counted every other day for 14 days. A murine liver cancer model was established by subcutaneous inoculation of Hepal-6 cells. A single dosage of 1 x 10(9) expression forming unit (efu) of Ad-mFL, Ad-null or PBS was injected intratumorally. The tumor volume and survival rate were measured twice a week. Twenty days after treatment of adenoviral vectors, three treated mice with their tumor disappearing were killed and their spleen was taken. The splenocytes from these tumor free mice were adoptively transferred to naive mice to whom Hepal-6 cells were inoculated 3 days thereaftter and then the tumor volume was measured once a week.for 4 weeks. 38 days after administration of adenoviral vectors, tumor free animals were rechallenged by parental Hepal-6 cells or syngenic EL4 lymphoma cells at the opposite sites of the original inoculation sites, and the tumor volume was also measured once a week for 4 weeks.RESULTS:Adenoviral vector efficiently infected Hepal-6 cells in intro, and lead to the secretion of high levels of mFL protein (80.5 +/- 7.3 ng/10(6)/24 h) in the supernatant. The growth of Hepal-6 tumor was significantly inhibited by one single intratumoral administration of Ad-mFL in 90% of the treated mice, and the tumor gradually grew in the two other groups. Two of the 7 mice (30%) in PBS group died in 17 days, 14% still lived in 37 days, and all died within 45 days. The mice in the Ad-null group began to die since the 21(st) day, only 11% of them were still alive in 60 days. All mice in the Ad-mFL group were alive at the 60(th) day after tumor implantation. Adoptive transfer of splenocytes to the animals receiving Ad-mFL treatment protected effectively them against a subsequent challenge with the identical tumor cells. Rechallenge of the Ad-mFL cured mice with the parental Hepal-6 cells resulted in complete inhibition of tumor growth. The growth of inoculated EL4 lymphoma cells gradually grew equally in the controls and the experimental mice.CONCLUSION:FL gene transfer mediated by recombinant adenoviral vector has potent therapeutic effects on Hepal-6 liver cancer, and develops long-lasting specific antitumor immunity, which may become a potent cancer gene therapy candidate for further clinic application.

Liver-specific Expression of an Exogenous Gene Controlled by Human Apolipoprotein A-I Promoter

In Vivo Distribution and Gene Expression of Genetically Modified Hepatocytes after Intrasplenic Transplantation

Protein liposomes-mediated targeted acetylcholinesterase gene delivery for effective liver cancer therapy

DNA Polymerases as targets for gene therapy of hepatocellular carcinoma

A Novel Approach for Inducing Enhanced and Selective Transgene Expression in Hepatocellular-Carcinoma Cells

Cell-Specific Expression of Artificial Micrornas Targeting Essential Genes Exhibit Potent Antitumor Effect on Hepatocellular Carcinoma Cells

Construction of a highly-active, liver-specific transcriptional regulatory element through combination of the albumin promoter and α-fetoprotein enhancer

Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line

Protein Transduction Domain of Membrane Penetrating Peptide Can Efficiently Deliver DNA and Protein into Mouse Liver for Gene Therapy.

An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy.

Egr1/HSP70 Promoter-Driven Activation of Gene Expression for Synergistic Anti-Hepatoma Using PEI-MZF Nanoparticles and Radiation

Development of a Gene Therapy Strategy to Target Hepatocellular Carcinoma Based Inhibition of Protein Phosphatase 2A Using the Α-Fetoprotein Promoter Enhancer and Pgk Promoter: an in Vitro and in Vivo Study

Experimental Study of Pcdna3/afp/tk/angio Fusion Gene Targeting Therapy for Human Primary Liver Cancer

Comparative studies of different carriers and introducing routes on the effects of liver targeted uptake of exogenous gene

Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer

[Gene Transfer of Murine Flt3 Ligand Mediated by Adenoviral Vector Efficiently Induces Growth Inhibition of Murine Liver Cancer].

Effect of recombinant plasmid pEGFP-AFP-hTNF on liver cancer cells (HepG2 Cells) in vitro when delivered by PEG-PEI/Fe₃O₄ nanomagnetic fluid

Receptor Targeting Using Copolymer-Modified Gold Nanoparticles for pCMV-Luc Gene Delivery to Liver Cancer Cells In Vitro

Non-viral FoxM1 gene delivery to hepatocytes enhances liver repopulation

Construction and verification of a hypoxia-induced gene therapy vector targeting hepatocellular carcinoma

A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene